+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030- Product Image
Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030- Product Image
Sale

Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010904
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biosimilars Market grew from USD 40.70 billion in 2023 to USD 49.91 billion in 2024. It is expected to continue growing at a CAGR of 23.31%, reaching USD 176.48 billion by 2030.

Biosimilars are biologic medical products highly similar to already approved reference biologics with no clinically meaningful differences in terms of safety, purity, and effectiveness. The rising prevalence of chronic diseases, coupled with the patent expiration of biologic drugs, is driving the necessity for biosimilars, offering a cost-effective alternative. These drugs are increasingly applied in conditions like cancer, autoimmune disorders, and diabetes, and are employed by hospitals, clinics, and research organizations. Key market growth influencers include the rising healthcare costs prompting a shift toward affordable treatment options, advancements in biotechnology and manufacturing processes, and supportive government regulations in many regions. Emerging markets, especially in Asia-Pacific and Latin America, offer substantial opportunities due to expanding healthcare infrastructure and increasing demand for affordable therapies. Companies can capitalize by investing in strategic partnerships, research, and localization in these growing markets.

However, the market is not without challenges. The high cost and complexity of development, along with stringent regulatory pathways, present significant barriers. Moreover, the strong brand loyalty enjoyed by original biologic manufacturers and patent litigations add layers of complexity. Intellectual property rights and regulatory exclusivity further pose hurdles. Innovation areas are promising in terms of enhancing process efficiencies, improving product quality, and developing next-generation biosimilars. Companies should also focus on education and awareness campaigns to increase physician and patient acceptance. Insights suggest a competitive but collaborative environment, where multinational firms often collaborate with local companies to enhance market penetration and compliance. The market emphasizes investment in research to improve biosimilar efficacy and expand their therapeutic uses. Overall, while the biosimilar market is complex due to regulatory and developmental challenges, it offers lucrative potential for reducing healthcare costs and expanding global access to essential biologic treatments.

Understanding Market Dynamics in the Biosimilars Market

The Biosimilars Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising healthcare expenditure into the pharmaceutical industry
    • Increasing demand for lower cost biosimilars drugs than original biologics
  • Market Restraints
    • Reluctance of physicians to prescribe biosimilars
  • Market Opportunities
    • Improvements in biosimilar production processes
    • Supportive government initiative to develop biosimilars
  • Market Challenges
    • Stringent regulatory requirements and laws

Exploring Porter’s Five Forces for the Biosimilars Market

Porter’s Five Forces framework further strengthens the insights of the Biosimilars Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Biosimilars Market

External macro-environmental factors deeply influence the performance of the Biosimilars Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Biosimilars Market

The Biosimilars Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Biosimilars Market

The Biosimilars Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Biosimilars Market

The Biosimilars Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Alvotech, Amgen Inc., Apotex Inc., Biocon Limited, BioFactura, Inc., Biogen Inc., Boehringer Ingelheim International GmbH., Catalent, Inc, Celltrion Healthcare Co.,Ltd., Coherus BioSciences, Dr. Reddy's Laboratories Limited, Eden Biologics, Inc., F. Hoffmann-La Roche AG, Fresenius Kabi, Innovent Biologics, Inc., Intas Pharmaceuticals Ltd., Kashiv BioSciences, LLC., Merck & Co., Inc., NeuClone, Nippon Kayaku Co., Ltd., Novartis AG, Panacea Biotec Limited, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
    • Recombinant Glycosylated Proteins
      • Erythropoietin
      • Follitropin
      • Monoclonal Antibodies
        • Adalimumab
        • Infliximab
        • Rituximab
    • Recombinant Non-Glycosylated Proteins
      • Granulocyte Colony-Stimulating Factor
      • Insulin
      • Interferons
        • Interferon-Alpha
        • Interferon-Beta
      • Recombinant Human Growth Hormone
    • Recombinant Peptides
      • Calcitonin
      • Glucagon
  • Indication
    • Autoimmune Diseases
    • Blood Disorders
    • Chronic Diseases
    • Growth Hormone Deficiency
    • Infectious Diseases
    • Oncology
  • Manufacturing
    • Contract Manufacturing
    • In-House Manufacturing
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising healthcare expenditure into the pharmaceutical industry
5.1.1.2. Increasing demand for lower cost biosimilars drugs than original biologics
5.1.2. Restraints
5.1.2.1. Reluctance of physicians to prescribe biosimilars
5.1.3. Opportunities
5.1.3.1. Improvements in biosimilar production processes
5.1.3.2. Supportive government initiative to develop biosimilars
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements and laws
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Biosimilars Market, by Product
6.1. Introduction
6.2. Recombinant Glycosylated Proteins
6.2.1. Erythropoietin
6.2.2. Follitropin
6.2.3. Monoclonal Antibodies
6.2.3.1. Adalimumab
6.2.3.2. Infliximab
6.2.3.3. Rituximab
6.3. Recombinant Non-Glycosylated Proteins
6.3.1. Granulocyte Colony-Stimulating Factor
6.3.2. Insulin
6.3.3. Interferons
6.3.3.1. Interferon-Alpha
6.3.3.2. Interferon-Beta
6.3.4. Recombinant Human Growth Hormone
6.4. Recombinant Peptides
6.4.1. Calcitonin
6.4.2. Glucagon
7. Biosimilars Market, by Indication
7.1. Introduction
7.2. Autoimmune Diseases
7.3. Blood Disorders
7.4. Chronic Diseases
7.5. Growth Hormone Deficiency
7.6. Infectious Diseases
7.7. Oncology
8. Biosimilars Market, by Manufacturing
8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing
9. Americas Biosimilars Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Biosimilars Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Biosimilars Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BIOSIMILARS MARKET RESEARCH PROCESS
FIGURE 2. BIOSIMILARS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIOSIMILARS MARKET DYNAMICS
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 65. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 66. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 67. CANADA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 68. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 69. CANADA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 70. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 71. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 73. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 74. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 76. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 79. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 107. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 109. CHINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 110. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 111. CHINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 112. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 113. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 115. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 117. INDIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 118. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 119. INDIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 120. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 121. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 131. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 133. JAPAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 134. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 135. JAPAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 136. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 137. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 145. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 153. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 161. SINGAPORE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. SINGAPORE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 169. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 177. TAIWAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. TAIWAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 179. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 180. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 181. THAILAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 182. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 183. THAILAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 184. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 185. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 193. VIETNAM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 194. VIETNAM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 204. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 205. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 206. DENMARK BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 207. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 208. DENMARK BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 209. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 210. DENMARK BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. DENMARK BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 212. EGYPT BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 213. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 214. EGYPT BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 215. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 218. EGYPT BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. EGYPT BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 220. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 221. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 223. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 224. FINLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 225. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 226. FINLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. FINLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 228. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 229. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 230. FRANCE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 231. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 232. FRANCE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 233. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 234. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 236. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 237. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 238. GERMANY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 239. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 240. GERMANY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 241. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 242. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 250. ISRAEL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 251. ISRAEL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 252. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 253. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 254. ITALY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 255. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 256. ITALY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 257. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 258. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 259. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 276. NORWAY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 277. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 278. NORWAY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 279. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 280. NORWAY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 281. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 282. NORWAY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 283. NORWAY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 284. POLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 285. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 286. POLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 287. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 288. POLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 289. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 290. POLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 291. POLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 292. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 293. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 294. QATAR BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 295. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 296. QATAR BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 297. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 298. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 299. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 307. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 314. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 322. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 324. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 325. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 326. SPAIN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 327. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 328. SPAIN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 329. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 330. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 331. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 335. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 336. SWEDEN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 337. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 338. SWEDEN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 339. SWEDEN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 340. SWITZERLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 341. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 343. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 344. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 345. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 346. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 347. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 348. TURKEY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 349. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 350. TURKEY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 351. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
TABLE 352. TURKEY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 353. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
TABLE 354

Companies Mentioned

The leading players in the Biosimilars market, which are profiled in this report, include:
  • Alvotech
  • Amgen Inc.
  • Apotex Inc.
  • Biocon Limited
  • BioFactura, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • Celltrion Healthcare Co.,Ltd.
  • Coherus BioSciences
  • Dr. Reddy's Laboratories Limited
  • Eden Biologics, Inc.
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi
  • Innovent Biologics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Kashiv BioSciences, LLC.
  • Merck & Co., Inc.
  • NeuClone
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Shanghai Henlius Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 49.91 Billion
Forecasted Market Value ( USD ) by 2030 $ 176.48 Billion
Compound Annual Growth Rate23.3%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Biosimilars - Global Strategic Business Report - Product Image

Biosimilars - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Biosimilars Market by Material Type (Silicon, Germanium, Transition Metal Oxides, Gold), Industry (Consumer Electronics, Automotive, Aviation, Energy, Medical Devices), Regional Outlook - Global Forecast up to 2032 - Product Image

Biosimilars Market by Material Type (Silicon, Germanium, Transition Metal Oxides, Gold), Industry (Consumer Electronics, Automotive, Aviation, Energy, Medical Devices), Regional Outlook - Global Forecast up to 2032

  • Report
  • 118 Pages
  • Global
From
Global Biosimilar Contract Manufacturing Market Analysis & Forecast to 2024-2034 - Product Image

Global Biosimilar Contract Manufacturing Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Biosimilars Global Market Report 2024 - Product Image

Biosimilars Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Biosimilars and Follow-On Biologics Market Report 2024-2034 - Product Image

Biosimilars and Follow-On Biologics Market Report 2024-2034

  • Report
  • 391 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.